Press Releases - WDM Group PR Network  

Takeda Cares Day Supports Local Charities

DEERFIELD, Ill., Oct. 5, 2012 /PRNewswire/ -- Takeda, a top 15 pharmaceutical company in the U.S., will raise money for local charities today when its employees participate in the annual Takeda Cares Day event. Nearly 600 employees will run or...

Apollo Hospitals Performs Complex Spinal Surgery on 10-Year-old

CHENNAI, October 5, 2012 /PRNewswire/ -- Renaissance™ Robotic Technology Introduced in Asia-Pacific The 12th Successful Completion of Complex Spinal Surgeries Within 10 Days Foreign Patients Have Also Been Treated Successfully Apollo Hospitals performed a complex spinal surgery on a 10-year-old child....

New Study Shows Marked Drop in PTSD Symptoms in Combat-Exposed Marines from Healing Touch and Guided Imagery

AKRON, Ohio, Oct. 5, 2012 /PRNewswire/ -- Three weeks of healing touch treatments, combined with listening to a guided imagery CD, provides significant clinical reductions in post-traumatic stress disorder (PTSD) symptoms for combat-exposed, active duty Marines, according to a study...

PENSRUS Pens October "Breast Cancer Awareness Month" With Sale on Pink Logoed Products

Contact information:
PENSRUS
www.pensrus.com
800-736-7787

Sirona Biochem to Present Scientific Poster at Canadian Diabetes Professional Conference

Sirona Biochem Corp.
Julie Jang
Director, Communications
604.282.6065
jjang@sironabiochem.com
www.sironabiochem.com

Ablynx Reports Excellent Interim Results From Phase I/II Study With Its anti-IL-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients

For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com

Boston Therapeutics Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET(TM) to Treat Diabetes

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

Investor Relations:
MZ Group
Scott Powell
Senior Vice President
Phone: 212-301-7130
Email: scott.powell@mzgroup.us
Web: www.mz-ir.com

Threshold Pharmaceuticals Announces Presentation and Webcast at 11th Annual BIO Investor Forum

Contact
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com

Zenmark Names REVESTIVE (teduglutide): A New Drug for the Treatment of Short Bowel Syndrome

Contact:
Doug Powell
Office: 415-434-4800
Email: Email Contact

Sialix Executes Option Agreement; Appoints New Management Team to Advance Sialic Acid-Based Products for Treatment and Prevention of Cancer and Inflammation

Sialix contact:
Jeff Behrens
Chief Executive Officer
Sialix, Inc.
617 500-3455
Email Contact

Media contact:
Michelle Linn
Linnden Communications
O. 508 362 3087
M. 774 696 3803
Email Contact

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | ...


Featured Articles + MORE Featured Articles >>